louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02457481: An Alternative Culture Medium to Better Support Preimplantation Embryo Development in Vitro
Official title: An Alternative Culture Medium to Better Support Preimplantation Embryo Development in Vitro
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infertility
Reproductive Techniques, Assisted
Keywords: Embryo Culture Techniques
Embryonic Development
Lead sponsor: National Foundation for Fertility Research
Sponsor class: OTHER
First posted: 2015-05-29
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to evaluate a newly developed embryo culture media system for human clinical use in ART.

Detailed description: Egg retrieval will be performed as per standard operating procedures. Eggs from a single patient are mixed together in a single group during the normal recovery and washing procedure following egg retrieval. The single group of eggs will be divided in half, then the embryologist will randomly place each half into one of the two culture media treatments, commercial or experimental. All mature eggs collected at retrieval will undergo fertilization per standard operating procedures according to physician recommendations. After fertilization (day 0), standard procedures involve in vitro embryo culture in a sequential two step media system. After confirmation of fertilization success on day 1, embryos are cultured until day 3 in step 1 medium (both commercial and experimental media are two step sequential culture systems). On day 3, embryos are evaluated and moved from step one to step two culture medium. On day 5 and day 6, embryo development will be assessed. Good quality blastocysts will either be transferred fresh or cryopreserved for later transfer and/or genetic testing.

Eligibility criteria: Inclusion Criteria:

* Adult women of any age who come to Colorado Center for Reproductive Medicine for fertility treatment using IVF.
* Patients can be of any race, culture, sexual orientation or ethnicity.

Exclusion Criteria:

* Minors are excluded from the study

Primary outcomes:
measure: embryo development
timeFrame: 7 days after egg retrieval
measure: pregnancy rate
timeFrame: 2 months after egg retrieval
measure: offspring weight
timeFrame: 1 year after egg retrieval
measure: offspring gender
timeFrame: 1 year after egg retrieval
Secondary outcomes:
measure: fertilization
timeFrame: 2 days after egg retrieval
measure: euploid embryos
timeFrame: 1 month after egg retrieval
Other outcomes:
Locations:
city: Lone Tree
country: United States
facility: Fertility Laboratories of Colorado
state: Colorado
city: Lone Tree
country: United States
facility: National Fooundation for Fertility Research
state: Colorado
Study officials:
affiliation: NFFR
name: Rebecca L Krisher, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05282381: Evaluation of Regret in Kidney Transplantation
Official title: Decisional Regret in a Prospective Cohort of Renal Transplant Recipients: the DONOR Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Renal Transplant Candidate for Right Kidney
Renal Transplant Candidate for Left Kidney
Keywords: Decisional regret
Kidney transplantation
Quality of life
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
First posted: 2022-03-16
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who received a kidney transplant in the nephrology department of the Lille University Hospital

Brief summary: Decisional regret is a negative feeling, involving distress or remorse following a decision. This has been studied in several areas such as psychology, economy or marketing. Patients suffering from end-stage renal disease may choose between dialysis and transplantation. This decision-making process is shared with the nephrologist, who explained to the patient the pros and cons of these two possibilities. Although transplantation offers a better life expectancy and quality of life than dialysis, nothing is known about the proportion of patients regretting their choice to be transplanted. The DONOR study aims to determine the proportion of patients regretting their decision, in a prospective cohort of renal transplant recipients. The decisional regret will be assessed by the DRS ("Decisional Regret Scale"), associated with the RetransQoL, a quality of life questionnaire.


Eligibility criteria: Inclusion Criteria:

* Kidney transplantation in the Lille University Hospital
* Functional kidney graft after 28 days post transplantation

Exclusion Criteria:

* Previous other solid organ transplant
* Combined transplantation (kidney and liver for example)
* Cognitive disorders
* Lack of French language skill

Primary outcomes:
measure: Decisional regret at 12 months post kidney transplantation, defined as a score ≥30 on the Decisional Regret Scale
timeFrame: At 12 months post-transplantation
Secondary outcomes:
measure: Specific Quality of Life Scale (ReTransQoL)
timeFrame: At 1, 3, 6 and 12 months post-transplantation
measure: Variation of decisional regret over time, following kidney transplantation, using the Decisional Regret Scale
timeFrame: At 1, 3, 6 and 12 months post-transplantation
measure: Identification of biological, psychological and sociological risk factors for decisional regret at 12 months post kidney transplantation, defined as a score ≥30 on the Decisional Regret Scale
timeFrame: At baseline, and during the 12 months follow-up period.
Other outcomes:
Locations:
city: Lille
country: France
facility: CHU Lille
Study officials:
affiliation: University Hospital, Lille
name: Mehdi Maanaoui, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01959581: Movement Enhancing Device for Children
Official title: An Innovative Device for Intervention in Infants With Nervous System Injury
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Upper Extremity Dysfunction
Keywords: Wilmington Robotic Exoskeleton
Reaching
Upper extremity function
Preterm Infants
Brain injury
Pediatrics
Early Intervention
Arthrogryposis
Lead sponsor: University of Delaware
Sponsor class: OTHER
Collaborators: name: Christiana Care Health Services
name: Alfred I. duPont Hospital for Children
First posted: 2013-10-10
Enrollment: 30
Sex: ALL
Minimum age (years): 1
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess: 1) how infants move their bodies to explore, play, and solve problems, 2) if this is different in a high-risk group of infants, and 3) if these abilities can be advanced in a high-risk group through the use of a movement assisting device.

Detailed description: Certain conditions or diagnoses identified soon after birth are known to put infants at risk for having problems with their motor (movement) development as they get older. Infants with these diagnoses are at risk for additional developmental problems due to their inability to move their bodies to explore, learn, and play. This study tests how a device that assists movement can help exploration, learning, and play in children. The information gathered in this study will help us better understand how early learning happens and how we can help individuals become better movers, learners, and problem-solvers so they can increase their participation in everyday play activities.

Eligibility criteria: Inclusion Criteria:

• Infants will be invited to participate if they are between 1 month and 6 years and:

* Were born \< 36 weeks of gestational age with periventricular leukomalacia or grade III or IV intraventricular hemorrhage
* Were born \> 36 weeks of gestational age with encephalopathy related to perinatal asphyxia
* Have the diagnosis of neonatal stroke or intracranial hemorrhage
* Have brachial plexus palsy
* Have arthrogryposis multiplex congenital
* Have Down syndrome
* Have congenital hypotonia

Exclusion Criteria:

• blindness or severe sensory motor impairments that would prohibit the child from completing the study assessment.

Primary outcomes:
measure: Change in Time Contacting Objects
timeFrame: 7 months
Secondary outcomes:
Other outcomes:
Locations:
city: Newark
country: United States
facility: Christiana Care Health Services
state: Delaware
city: Newark
country: United States
facility: University of Delaware
state: Delaware
city: Wilmington
country: United States
facility: Nemours Foundation
state: Delaware
Study officials:
affiliation: University of Delaware
name: Michele A Lobo, PT, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03984981: Brain Death Diagnosis at an Academic Tertiary Medical Care Center
Official title: Brain Death Diagnosis at an Academic Tertiary Medical Care Center
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Brain Death
Keywords: diagnosis of brain death
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2019-06-13
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The study population will consist of all adult (18 years or older) patients in whom brain death was suspected and/or diagnosed on the ICUs of the University Hospital Basel between January 1st 2008 and January 31st 2019.

Brief summary: The aim of this study is to assess and survey the quality of the process required to diagnose brain death in adult patients. This study of adult patients diagnosed brain dead or suspected of having brain death on the ICUs at the University Hospital Basel will be purely observational.


Eligibility criteria: Inclusion Criteria:

* patients with suspected and/or diagnosed brain death
* adults 18 years and over

Primary outcomes:
measure: adherence to the local brain death protocol ( = measurement tool) for the process of brain death diagnosis
timeFrame: single time point assessment at baseline (after suspected brain death)
Secondary outcomes:
measure: number of physicians involved
timeFrame: single time point assessment at baseline (after suspected brain death)
measure: frequency of ancillary tests performed
timeFrame: single time point assessment at baseline (after suspected brain death)
measure: number of work-ups excluding suspected brain death
timeFrame: single time point assessment at baseline (after suspected brain death)
measure: number of diagnostic work-ups with insufficient performance and/or documentation
timeFrame: single time point assessment at baseline (after suspected brain death)
measure: years of clinical experience of physicians involved
timeFrame: single time point assessment at baseline (after suspected brain death)
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: Clinic for Intensive Care Medicine, University Hospital Basel
Study officials:
affiliation: Clinic for Intensive Care Medicine, University Hospital Basel
name: Raoul Sutter, PD Dr. med
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00526695: Effects of Sevoflurane in Subanesthetic Concentrations on the Forearm Perfusion
Official title: Effects of Sevoflurane in Subanesthetic Concentrations on the Forearm Perfusion, Leukocyte/Thrombocyte Activation, and Endothelial Function After Tourniquet-Induced Ischemia/Reperfusion Injury in the Forearm of Volunteers
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Ischemia/Reperfusion Injury
Keywords: Ischemia/Reperfusion
Organ Protection
Anesthetics
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2007-09-10
Enrollment: 10
Sex: MALE
Minimum age (years): 25
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Sevoflurane preconditioning and cardiovascular protection against ischemia/reperfusion injury.

Study hypothesis: The volatile anesthetic sevoflurane at subanesthetic concentrations achieves endothelial protection against ischemia/reperfusion injury and reduces inflammatory markers in the circulation

Detailed description: Healthy volunteers are included in the study to investigate endothelial function and platelet activation after preconditioning by sevoflurane in subanesthetic concentrations.

Forearm perfusion, endothelial function and leukocyte/thrombocyte activation after tourniquet-induced ischemia/reperfusion injury of the forearm are measured using healthy volunteers in a cross-over design.

Eligibility criteria: Inclusion criteria: male

* Non-smoker
* No asthma
* NPO
* Volunteer

Exclusion criteria:

* Female
* Chronic medication
* Asthma
* Smoking

Primary outcomes:
measure: marker expression on blood cells
timeFrame: December 2008
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital of Zurich
Study officials:
affiliation: UniversitaetsSpital Zuerich
name: Michael Zaugg, PD Dr. med.
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Zurich
name: Michael Zaugg, PD Dr. med.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lucchinetti E, Zeisberger SM, Baruscotti I, Wacker J, Feng J, Zaugg K, Dubey R, Zisch AH, Zaugg M. Stem cell-like human endothelial progenitors show enhanced colony-forming capacity after brief sevoflurane exposure: preconditioning of angiogenic cells by volatile anesthetics. Anesth Analg. 2009 Oct;109(4):1117-26. doi: 10.1213/ANE.0b013e3181b5a277.
Clinical trial NCT06962995: Multi-Cancer Detection Observational Cohort Study
Official title: Multi-Cancer Detection Observational Cohort Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cancer
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2025-05-08
Enrollment: 5000
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult participants who have undergone multi-cancer detection testing (MCD) as part of their clinical care at or outside Mayo Clinic

Brief summary: This study assesses the incorporation of Multi-Cancer Detection (MCD) testing, designed to detect many types of cancer, into clinical practice to understand both its use and effect in real world practice conditions.


Eligibility criteria: Inclusion Criteria:

* Has Mayo Clinic medical record number
* Has undergone (within last 6 months) or scheduled to undergo a multi-cancer detection test (MCD) as ordered by provider
* Able to provide informed consent
* ≥ 21 years old
* Ability to provide blood sample

Exclusion Criteria:

* Individuals who have situations that would limit compliance with the study requirements
* Institutionalized (i.e. Federal Medical Prison)
* Known pregnancy (self-reported)
* Currently undergoing active cancer treatment other than adjuvant hormone therapy
* Invasive cancer diagnosis within the last 3 years

Primary outcomes:
measure: Financial impact of MCD testing
timeFrame: Up to 5 years
measure: Positive actionable MCD results
timeFrame: Up to 5 years
measure: Psychological Impact of MCD Testing
timeFrame: Baseline (after receiving MCD results)
measure: Change in Patient Satisfaction with MCD Test
timeFrame: Baseline; After receiving MCD results (up to 5 years)
Secondary outcomes:
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Mayo Clinic in Arizona
state: Arizona
city: Jacksonville
country: United States
facility: Mayo Clinic in Florida
state: Florida
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Jewel Samadder, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01234181: Clinical Study of Hypoxia-Stressed Bone Marrow Mononuclear Cell Transplantation to Treat Heart Diseases
Official title: Clinical Study of Hypoxia-Stressed Bone Marrow Mononuclear Cell Intracoronary Transplantation in Myocardial Infarction and Other Heart Diseases.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Myocardial Infarction (MI) or Acute Myocardial Infarction (AMI)
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2010-11-04
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study, is to determine the differences of clinical outcomes between hypoxic pre-treatment group and control group in bone marrow stem cell transplantation (BM-SCT) to treat acute myocardial infarction (AMI); and to evaluate the safety of both treatments. Heart failure patients underwent PCI treatment after AMI and with informed consent, are randomized allocation into hypoxic pre-treated BM-SCT group, normoxic pre-treated BM-SCT group, and control group. Cell resuspension is intracoronary injected into patients receiving coronary angiography, IL-6, CRP, TNF and BNP are detected; echocardiography, cardiac MRI and ECT are analyzed to evaluate heart function and alive myocardial cells. Holter's ECG monitor is employed to observe arrhythmia and embolism. We hypothesize that, by receiving hypoxic pre-treated BM-SCT, impaired heart function will be reversed in heart failure patients.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of acute Myocardial Infarction(within one month);
* Age under 65;
* Infarction related wall motion abnormality on echocardiography;
* Infarction related TIMI flow grades 3 on coronary angiography during cell injection;
* Informed consent;

Exclusion Criteria:

* Active infection, or hematopoietic malignancy;
* Patients have tumor or other lethal diseases;
* Informed refusal

Primary outcomes:
measure: Heart function
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: 2nd Affiliated Hospital, School of Medicine at Zhejiang University
name: Jian'an Wang, M.D, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hu X, Yu SP, Fraser JL, Lu Z, Ogle ME, Wang JA, Wei L. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg. 2008 Apr;135(4):799-808. doi: 10.1016/j.jtcvs.2007.07.071.
citation: Hu X, Huang X, Yang Q, Wang L, Sun J, Zhan H, Lin J, Pu Z, Jiang J, Sun Y, Xiang M, Liu X, Xie X, Yu X, Chen Z, Tse HF, Zhang J, Wang J. Safety and efficacy of intracoronary hypoxia-preconditioned bone marrow mononuclear cell administration for acute myocardial infarction patients: The CHINA-AMI randomized controlled trial. Int J Cardiol. 2015 Apr 1;184:446-451. doi: 10.1016/j.ijcard.2015.02.084. Epub 2015 Feb 25.
Clinical trial NCT05024981: Videographic Feedback and Walk Rehabilitation in Post-Cerebrovascular Accident
Official title: Videographic Feedback and Walk Rehabilitation in Post-Cerebrovascular Accident
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cerebrovascular Accident
Lead sponsor: Centre Hospitalier Universitaire de Nice
Sponsor class: OTHER
First posted: 2021-08-27
Enrollment: 64
Sex: ALL
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Cerebrovascular Accident affects the majority of the elderly population and its frequency is constantly increasing. The resulting deficits are numerous and lead in particular to an alteration in the quality of walking and autonomy. Numerous rehabilitation techniques have been described. In practice, correction instructions are often given by the therapist while the motor activity is being performed. Walking is a complex activity, as is the processing of dual-task information in elderly stroke patients. It therefore appears interesting to separate the time of motor realization and that of correction instructions. Investigators therefore propose firstly to film the patient during the performance of a walking activity and then, secondly, to analyse the video with the patient, which thus represents a source of delayed feedback. The main objective of the study is to observe the effects of this practice on walking speed. Investigators are comparing two groups of patients: the control group receiving conventional rehabilitation and the experimental group receiving conventional rehabilitation plus sessions with the video tool. They expect to observe a greater improvement in walking speed in the experimental group.


Eligibility criteria: Inclusion Criteria:

* Hospitalization for a first episode of Cerebrovascular Accident less than six months old, or nth stroke less than six months old, with no previous sequelae;
* Able to walk at least 10m without stopping, with or without technical assistance, but without human assistance, under supervision;

Exclusion Criteria:

* Palliative or life-threatening situation;
* A patient whose guardian or trustee is not readily available to provide information about the patient
* Neuro-cognitive disorder that prevents understanding of instructions, as determined by the clinician;
* Severe speech or language disorder that prevents the protocol from being carried out correctly;
* Hemineglect;
* Any previously known pathology altering the gait pattern, at the clinician's discretion (recent neurological, traumatological or orthopaedic pathologies, etc.);
* Visual disorder preventing viewing of the video;
* Hearing disorder preventing comprehension.

Primary outcomes:
measure: Walking speed
timeFrame: Day 26
Secondary outcomes:
Other outcomes:
Locations:
city: Nice
country: France
facility: CHU Nice
state: Alpes-Maritime
Study officials:
affiliation: Centre Hospitalier Universitaire de Nice
name: Audrey MARTEU
role: PRINCIPAL_INVESTIGATOR
References: